Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Mylan to Buy Abbott’s Generic Drug Business Outside U.S. for $5.3 Billion

14/07/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzmvmtyvnti3l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0

Abbott Laboratories said on Monday that it had agreed to sell its established generic drug business outside the United States to the generic drug maker Mylan in an all-stock deal that valued at about $5.3 billion.

Under the deal, Abbott will take a 21 percent stake worth about $5.3 billion in a new company that combines Mylan’s existing business with Abbott’s developed markets pharmaceuticals operations in Europe, Japan, Canada, Australia and New Zealand.

The transaction will allow Mylan to engage in a so-called inversion: the Pennsylvania company would reincorporate in the Netherlands to lower its corporate taxes and to free up cash held in overseas entities.

Mylan, whose headquarters are in Pittsburgh, unsuccessfully pursued the Swedish drug maker Meda this year in hopes of engaging in an inversion.

“We have been actively looking at a wide range of opportunities, and the acquisition of this business is absolutely the right next strategic transaction for Mylan as it builds on our strong momentum, expands and further diversifies our business in our largest markets outside of the U.S.,” Robert J. Coury, the Mylan executive chairman, said in a statement.

This article has been extracted from http://dealbook.nytimes.com, please click on this link to read the article in full http://dealbook.nytimes.com/2014/07/14/mylan-to-buy-generics-drugs-business-outside-u-s-from-abbott-for-5-3-billion/

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdkvmjkvmdgvmtmvmjkvmjgyl1vudgl0bgvkigrlc2lnbiaomjuplmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

Are PSLs a Blocker or an Enabler?

2017-10-02 11:00:00 +0100

The use of a Preferred Supplier List (PSL) was intended to support and strengthen relationships and performance between organisations and their third party suppliers. As the technical landscape continues to evolve at rapid rate recruitment and demand for new skills becomes more intense. Are PSLs still the solution or an obstacle to sourcing the right talent? The traditional PSL A dedicated list of partners intended to guarantee quality and availability ...

W1siziisijiwmtcvmdkvmjevmdgvndmvmduvmtmxl1vudgl0bgvkigrlc2lnbiaomjmplmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

Why do we punish the victims of hacking?

2017-09-21 09:00:00 +0100

Hacks occur every 39 seconds, with 95% of them targeting governments, retailers and the tech industry. If the hackers are caught, they'll face prison time under the Computer Misuse Act. More often than not, the businesses who are victims of those attacks expose themselves to punishment of their own. The laws that determine the duty of protection owed to businesses and their customers is both vague and broad, making them question just how much protection...